Welcome to our dedicated page for Unicycive Therapeutics news (Ticker: UNCY), a resource for investors and traders seeking the latest updates and insights on Unicycive Therapeutics stock.
Unicycive Therapeutics, Inc. (UNCY) is a clinical-stage biotechnology company whose news flow centers on the development and regulatory progress of kidney disease therapies. Company press releases highlight advances for its lead investigational product oxylanthanum carbonate (OLC), an oral phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis, and for its second program UNI-494, which is intended for conditions related to acute kidney injury.
Investors following UNCY news can expect detailed updates on regulatory interactions with the U.S. Food and Drug Administration, including New Drug Application submissions, Complete Response Letters, Type A meetings, and NDA resubmissions for OLC. The company also reports on pivotal and Phase 2 clinical trial results, analyses of pill burden and phosphate control, and publications of OLC data in peer-reviewed journals such as the Clinical Journal of the American Society of Nephrology.
Unicycive’s news releases frequently cover financial results, cash runway commentary, and capital markets activities, such as at-the-market equity offerings and reverse stock split implementation, as disclosed in associated Form 8-K filings. Additional news items include participation in healthcare and investor conferences, issuance of new patents for UNI-494 and its use in chronic kidney disease, and corporate updates on Nasdaq listing compliance and legal matters, including disclosure of a purported securities class action.
This UNCY news page aggregates these company-issued updates so readers can review clinical data milestones, regulatory developments, intellectual property announcements, and financial disclosures in one place. For those tracking the progress of oxylanthanum carbonate and UNI-494, the news feed provides a chronological view of Unicycive’s communications about its kidney disease pipeline and corporate activities.
Unicycive Therapeutics (Nasdaq: UNCY) announced promising preclinical results for its drug UNI-494, targeted at treating Acute Kidney Injury (AKI). In a study involving a rodent model of AKI, UNI-494 significantly reduced levels of β-2 microglobulin, a key biomarker for kidney damage. The company aims to file for regulatory approval by the end of 2022 to start a Phase 1 human study. UNI-494 works by activating mitochondrial KATP channels, potentially offering therapeutic benefits beyond AKI, including chronic kidney and liver diseases.
Unicycive Therapeutics, a clinical stage biotechnology company focused on therapies for kidney disease, announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. CEO Shalabh Gupta will provide a corporate overview via a virtual presentation available on demand starting at 7:00 am ET on September 12. The presentation will be accessible for 90 days on their website. Unicycive is developing innovative treatments for hyperphosphatemia and acute kidney injury.
Unicycive Therapeutics has announced the acceptance of two abstracts for presentation at the American Society of Nephrology’s Kidney Week 2022, along with a publication in the Abstract Supplement. The abstracts focus on the company’s innovative product candidates: UNI-494, aimed at reducing oxidative stress in kidney disease, and Renazorb, a phosphate binder for treating hyperphosphatemia in chronic kidney disease patients. These presentations highlight key findings that support their ongoing clinical development and potential market impact.
Unicycive Therapeutics (Nasdaq: UNCY) announced significant advancements in its product pipeline, focusing on Renazorb, a nanoparticle-based phosphate binder for Chronic Kidney Disease (CKD). The company is on track to file a New Drug Application (NDA) by the end of 2023 after signing a partnership with Lee’s Pharmaceutical for rights in China. Financially, Unicycive reported a net loss of $3.6 million for Q2 2022, with R&D expenses rising to $1.9 million. The company holds $10.6 million in cash as of June 30, 2022, ensuring funding for ongoing projects.
Summary not available.
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) has announced positive findings from a market research study indicating strong prescribing intent for its phosphate binder, Renazorb, pending FDA approval. Conducted by Reason Research, the study revealed nephrologists expect to prescribe Renazorb to 34% of dialysis patients needing phosphate binders. Key unmet needs identified include a lower pill burden and improved patient compliance, with Renazorb potentially addressing these issues. The hyperphosphatemia treatment market exceeds $1 billion in the U.S., presenting a significant commercial opportunity for Renazorb.
Unicycive Therapeutics has entered a partnership with Lee's Pharmaceutical to develop and market Renazorb® for hyperphosphatemia in patients with chronic kidney disease across Asia, including China. Unicycive will receive a $1 million upfront payment, potential milestone payments, and tiered royalties based on sales performance. The agreement capitalizes on Lee’s Pharm’s expertise in the region, where the renal disease market is expanding due to rising chronic kidney disease rates. Renazorb is designed to improve patient compliance by reducing pill burden, a critical factor for effective treatment.
Unicycive Therapeutics, a clinical-stage biotechnology company focused on kidney disease therapies, will present at the JMP Securities Life Sciences Conference on June 16, 2022, at 10:30 am ET. CEO Shalabh Gupta will showcase the company’s innovative treatments, including its lead drug Renazorb for hyperphosphatemia and the new entity UNI-494 for acute kidney injury. The event will be held in New York City, and the presentation will be available via live webcast on the company’s website.
Unicycive Therapeutics has initiated a pivotal clinical bioequivalence study for Renazorb, a phosphate binding agent, to treat hyperphosphatemia in patients with kidney disease. This single study, approved by the FDA, aims to demonstrate pharmacological efficacy compared to Fosrenol. The study will enroll 64 participants and evaluate urinary phosphate excretion changes. Previous trials showed Renazorb was safe and effective at reducing urine phosphate, addressing a significant unmet need in a market exceeding $1 billion. Unicycive is also preparing for commercialization.
Unicycive Therapeutics (Nasdaq: UNCY) reported its financial results for Q1 2022, revealing a net loss of $3.5 million ($0.24 per share), up from $1.0 million ($0.11 per share) in Q1 2021. Research and development expenses rose to $1.9 million, mainly due to ongoing drug development for Renazorb and UNI-494. The company is set to begin a bioequivalence study for Renazorb in Q2 2022 and anticipates filing a 505(b)(2) NDA. With $13.6 million in cash, Unicycive is adequately funded for upcoming milestones, including the clinical trial for UNI-494 planned for later in 2022.